Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 290

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 290
---
             
 pending the ultimate approval of the project completion, the Company has not yet recognized income from this grant.                           
 In April 2024, the Company received the approval                                                                                              
 (refer to Note 14).                                                                                                                           |

| 5. | In January 2024, the Company renewed its facility lease agreement until December 2024. The monthly rental obligations under non-cancellable leases are approximately $5.5 (including $3 for administrative expenses). |

As part of the agreement, the Company
has provided the landlord with a bank guarantee of approximately of $7 (NIS 27 thousand) which is valid until February 2025.

Future minimum lease payments under non-cancelable
operating leases as of December 31, 2023 are as follows:

| 2024 |     | USD | 66 |
|:-----|:----|:----|---:|
|      |     | $   | 66 |

The Company elected to apply the practical
expedients permitted under the transition guidance in ASU 2016-02, and the Company also elected not to apply the recognition requirements
in ASU 2016-02 to short-term leases (less than 12 months) as of the adoption date. As such, there was no impact on the Company’s
financial statements as a result of adopting ASU 2016-02.

| 6. | In 2019, a controversy has arisen between the Company and CSL Behring                                                                         
 GmbH, or CSL, whether certain unshipped minimum purchase commitments for fibrinogen from 2018 to 2020 are to be paid by the Company pursuant  
 to a Framework Supply Agreement dated March 8, 2016, or Framework Supply Agreement, by and between the Company and CSL, whereby CSL agreed    
 to supply the Company with fibrinogen. On January 14, 2020, the Company received a termination letter, or CSL Termination Letter. In the      
 CSL Termination Letter, CSL demanded a total amount of $820, claiming it was owed the minimum purchase commitment amounts under the Framework 
 Supply Agreement not paid by the Company in 2018 and 2019. In a subsequent correspondence, CSL additionally demanded interest and damages     
 for lost profit, with an aggregate demand amount of $1,476. The Company has disputed CSL’s payment demand and contends that CSL’s             
 demands are baseless under the Framework Supply Agreement, as the minimum purchase commitment under the Framework Supply Agreement is         
 conditional upon first